Bristol-Myers Squibb Company [BMY] is 19.57% higher this YTD. Is it still time to buy?

Bristol-Myers Squibb Company [NYSE: BMY] plunged by -$0.78 during the normal trading session on Monday and reaching a high of $75.86 during the day while it closed the day at $74.55. The company report on August 17, 2022 that Bristol Myers Squibb Completes Acquisition of Turning Point Therapeutics, Expanding Precision Oncology Portfolio.


Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now.

Sponsored


Bristol Myers Squibb (NYSE:BMY) announced today that it has successfully completed its acquisition of Turning Point Therapeutics, Inc. (“Turning Point”), in an all-cash transaction. With the completion of the acquisition, Turning Point shares have ceased trading on the NASDAQ Global Select Market and Turning Point is now a wholly owned subsidiary of Bristol Myers Squibb.

“Turning Point has distinguished itself in the field of precision oncology, and this acquisition will further strengthen our leading oncology franchise,” said Elizabeth Mily, Executive Vice President, Strategy & Business Development, Bristol Myers Squibb. “With Turning Point’s lead asset, repotrectinib, Bristol Myers Squibb will be positioned to address a significant unmet medical need for ROS1-positive non-small cell lung cancer patients. We look forward to bringing this promising, innovative medicine to patients in the second half of 2023.”.

Bristol-Myers Squibb Company stock has also gained 0.03% of its value over the past 7 days. However, BMY stock has declined by -2.15% in the 3 months of the year. Over the past six months meanwhile, it has gained 10.36% and gained 19.57% year-on date.

The market cap for BMY stock reached $156.69 billion, with 2.13 billion shares outstanding and 2.13 billion shares in the current float. Compared to the average trading volume of 11.14M shares, BMY reached a trading volume of 5703650 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about Bristol-Myers Squibb Company [BMY]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BMY shares is $81.38 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BMY stock is a recommendation set at 2.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Raymond James have made an estimate for Bristol-Myers Squibb Company shares, keeping their opinion on the stock as Mkt Perform, with their previous recommendation back on June 03, 2022. While these analysts kept the previous recommendation, Morgan Stanley raised their target price to Underweight. The new note on the price target was released on April 06, 2022, representing the official price target for Bristol-Myers Squibb Company stock. Previously, the target price had yet another raise to $72, while Goldman analysts kept a Buy rating on BMY stock.

The Average True Range (ATR) for Bristol-Myers Squibb Company is set at 1.40, with the Price to Sales ratio for BMY stock in the period of the last 12 months amounting to 3.32. The Price to Book ratio for the last quarter was 4.88, with the Price to Cash per share for the same quarter was set at 6.31. Price to Free Cash Flow for BMY in the course of the last twelve months was 16.06 with Quick ratio for the last quarter at 1.30.

BMY stock trade performance evaluation

Bristol-Myers Squibb Company [BMY] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 0.03. With this latest performance, BMY shares gained by 2.19% in over the last four-week period, additionally plugging by 10.36% over the last 6 months – not to mention a rise of 7.73% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BMY stock in for the last two-week period is set at 50.89, with the RSI for the last a single of trading hit 51.73, and the three-weeks RSI is set at 50.16 for Bristol-Myers Squibb Company [BMY]. The present Moving Average for the last 50 days of trading for this stock 74.79, while it was recorded at 74.54 for the last single week of trading, and 69.60 for the last 200 days.

Bristol-Myers Squibb Company [BMY]: An insightful look at the core fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Bristol-Myers Squibb Company [BMY] shares currently have an operating margin of +20.57 and a Gross Margin at +57.69. Bristol-Myers Squibb Company’s Net Margin is presently recorded at +15.08.

Return on Equity for this stock inclined to 18.96, with Return on Assets sitting at 6.14.

Bristol-Myers Squibb Company’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.30 and a Current Ratio set at 1.40.

Earnings per share (EPS) analysis for Bristol-Myers Squibb Company [BMY] stock

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BMY. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Bristol-Myers Squibb Company go to 4.88%.

Bristol-Myers Squibb Company [BMY]: Insider Ownership positions

There are presently around $123,882 million, or 79.80% of BMY stock, in the hands of institutional investors. The top three institutional holders of BMY stocks are: VANGUARD GROUP INC with ownership of 196,828,094, which is approximately -0.837% of the company’s market cap and around 0.10% of the total institutional ownership; BLACKROCK INC., holding 170,645,262 shares of the stock with an approximate value of $12.72 billion in BMY stocks shares; and JPMORGAN CHASE & CO, currently with $7.29 billion in BMY stock with ownership of nearly 4.129% of the company’s market capitalization.

Positions in Bristol-Myers Squibb Company stocks held by institutional investors increased at the end of July and at the time of the July reporting period, where 1,125 institutional holders increased their position in Bristol-Myers Squibb Company [NYSE:BMY] by around 118,030,925 shares. Additionally, 1,176 investors decreased positions by around 90,953,682 shares, while 352 investors held positions by with 1,452,743,551 shares. The mentioned changes placed institutional holdings at 1,661,728,158 shares, according to the latest SEC report filing. BMY stock had 151 new institutional investments in for a total of 9,170,265 shares, while 98 institutional investors sold positions of 8,263,791 shares during the same period.

LEAVE A REPLY

Please enter your comment!
Please enter your name here